First quarter financial results 2026 for Medistim ASA

The quarter ended with sales exceeding MNOK 200 for the first time. Total sales ended at MNOK 201.7 (MNOK 181.5), 11.1 % above Q1-2025.

Currency neutral sales of own products were up 28.8 % for the quarter. Strong currency neutral growth in all geographies with APAC leading the way with 57.5 % growth, AMERICAS grew by 30.9 %, while EMEA was up 11.5 %.

Third-party distributor sales in Scandinavia faced an exceptionally strong comparable from Q1-2025 and decreased by 30.2 % for the quarter.

Operating profit (EBIT) ended at MNOK 57.1 for the quarter, resulting in 28.3 % EBIT margin (MNOK 59.2, 32.6 % margin). Currency neutral EBIT was MNOK 61.4.

In February 2026, Medistim announced the establishment of a direct sales operation in Japan, effective from March 16, 2026.

Recurring sales remained high at 67.8 % (67.7 %).

Solid cash position at quarter end with MNOK 209.8. The company has no interest-bearing bank loans.

The General Assembly decided on a dividend of NOK 8.00 per share, total dividend payment of MNOK 146.2.